REMARKS

Independent claims 1 and 37 were amended in the submission made with the request for continued examination to make itclear that the LDL values are plasma LDL values. In case that amendment was misplaced or not entered for some reason, it is reatated in the claims presented in this paper. Since the issue has already been dealt with, however, it is submitted that the finality of the present action should be withdrawn.

Having regard to the election of species requirement, applicant elects the specific compound set out in paragraph 17 of the specification namely the 2-n-butyl analog of galanthamine. This compound is comprised within the definitions of compounds given in claims 1 - 18, 22 - 24, 28 - 33, and 37.

Respectfully submitted

John Richards

LADAS/& PARRY

26 West 61st. Street

New York, New York 10023

Reg. 31053

Tel. (212) 708-1915